Daniel Clark

Stock Analyst at Leerink Partners

(3.40)
# 2,395
Out of 4,835 analysts
48
Total ratings
58.8%
Success rate
14.7%
Average return

Stocks Rated by Daniel Clark

Amneal Pharmaceuticals
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $17.01
Upside: +35.21%
ANI Pharmaceuticals
Sep 9, 2026
Reiterated: Buy
Price Target: $104
Current: $71.18
Upside: +46.11%
Bausch + Lomb
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $17.35
Upside: +38.33%
Collegium Pharmaceutical
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $22.75
Upside: +97.80%
Harrow
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $34.48
Upside: +30.51%
Pacira BioSciences
Sep 9, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $25.22
Upside: +11.05%
Phathom Pharmaceuticals
Sep 9, 2026
Initiated Coverage: Hold
Price Target: $10
Current: $8.36
Upside: +19.62%
Teva Pharmaceutical Industries
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $37.09
Upside: +21.33%
Viatris
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $16.51
Upside: +21.14%
Elanco Animal Health
Feb 24, 2026
Reiterated: Buy
Price Target: $24$30
Current: $23.17
Upside: +29.48%
Reiterated: Buy
Price Target: $745$785
Current: $504.70
Upside: +55.54%
Reiterated: Hold
Price Target: $153$152
Current: $72.97
Upside: +108.30%